Juan C. Jaen - Jun 16, 2021 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
President, Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Stock symbol
RCUS
Transactions as of
Jun 16, 2021
Transactions value $
-$116,051
Form type
4
Date filed
6/21/2021, 04:50 PM
Next filing
Dec 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Sale -$50.6K -2.1K -1.03% $24.13 201K Jun 16, 2021 Direct F1, F2
transaction RCUS Common Stock Sale -$2.15K -87 -0.04% $24.77 201K Jun 16, 2021 Direct F1, F3
transaction RCUS Common Stock Sale -$63.3K -2.68K -1.33% $23.68 198K Jun 17, 2021 Direct F1, F4
holding RCUS Common Stock 1.57M Jun 16, 2021 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.